Merck taps Xeris for ready-to-use versions of antibody productsnews2021-10-26T12:47:37+00:00October 26th, 2021|Fierce Pharma|
Fledgling CDMO ten23 health acquires swissfillon to boost biologic capabilitiesnews2021-10-26T12:01:29+00:00October 26th, 2021|Fierce Pharma|
Fujifilm starts build-out for massive NC plant, the latest piece of its multibillion-dollar CDMO expansion effortnews2021-10-26T11:17:27+00:00October 26th, 2021|Fierce Pharma|
AmMax, targeting a Daiichi market, posts data on delivery of rare tumor drugnews2021-10-26T10:05:43+00:00October 26th, 2021|Fierce Pharma|
Novartis-backed Credence taps Phillips-Medisize to step up production drug delivery systemnews2021-10-26T10:02:02+00:00October 26th, 2021|Fierce Pharma|
Is Sandoz spinoff finally here? Novartis gets the ball rolling with strategic reviewnews2021-10-26T09:21:31+00:00October 26th, 2021|Fierce Pharma|
BioNTech to start building mRNA vaccine manufacturing plant in Africa in mid-2022news2021-10-25T21:53:46+00:00October 25th, 2021|Fierce Pharma|
Arrowhead takes aim at Wisconsin for $250M manufacturing plant: reportnews2021-10-25T17:44:08+00:00October 25th, 2021|Fierce Pharma|
AstraZeneca’s Imfinzi strikes immunotherapy’s first win in bile duct cancer, with Merck’s Keytruda behindnews2021-10-25T15:30:20+00:00October 25th, 2021|Fierce Pharma|
Tiny biotech Errant sues Bluebird for patent infringement in developing gene therapy LentiGlobinnews2021-10-25T15:15:45+00:00October 25th, 2021|Fierce Pharma|
